BRAF encodes a serine/threonine kinase that is a direct effector of Ras, and the T599R activating BRAF mutation is associated with aberrant activation of the Ras/MAPK pathway, resulting in a hypertrophic cardiomyopathy (HCM) phenotype. The gene discussed is MARK2; the disease is hypertrophic cardiomyopathy.